Kinetic Concepts' international sales surge as U.S. revenue dips
This article was originally published in The Gray Sheet
International sales helped Kinetic Concepts Inc. achieve a 3.3% revenue gain in the first quarter over last year - to $485.8 million (or just below 1% at constant currency), the firm reported April 27. The total includes nearly $109.6 million in international sales, up 9.5% (or 1.3% at constant currency). But North American sales in KCI's Active Healing Solutions division, the company's largest, dipped 2% to $249.8 million during the quarter. A slowdown in U.S. demand for the firm's market-leading V.A.C. negative pressure wound therapy system was a factor behind the decline, CEO Catherine Burzik said, fueled in part by competition and more people either uninsured or on Medicaid due to high unemployment. The firm plans to fuel growth in part with a continued focus on Asian markets and new product launches, such as the next-generation V.A.C. Via, cleared by FDA in March. KCI's Regenerative Medicine division was one domestic bright spot, with U.S. sales of $78 million, up 18%. Globally, the latter division had revenue of $79 million, up 19.3%
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.